Cargando…
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
BACKGROUND: In this phase I/II trial, we evaluated the safety and effectiveness of pembrolizumab, with or without concurrent radiotherapy (RT), for lung and liver lesions from metastatic non-small cell lung cancer (mNSCLC). METHODS: Patients with lung or liver lesions amenable to RT plus at least on...
Autores principales: | Welsh, James, Menon, Hari, Chen, Dawei, Verma, Vivek, Tang, Chad, Altan, Mehmet, Hess, Kenneth, de Groot, Patricia, Nguyen, Quynh-Nhu, Varghese, Rejani, Comeaux, Nathan I, Simon, George, Skoulidis, Ferdinandos, Chang, Joe Y, Papdimitrakopoulou, Vasiliki, Lin, Steven H, Heymach, John V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555111/ https://www.ncbi.nlm.nih.gov/pubmed/33051340 http://dx.doi.org/10.1136/jitc-2020-001001 |
Ejemplares similares
-
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
por: Barsoumian, Hampartsoum B, et al.
Publicado: (2020) -
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
por: Altan, Mehmet, et al.
Publicado: (2023) -
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
por: Alessi, Joao V, et al.
Publicado: (2020) -
Phase 2 study of pembrolizumab in patients with advanced rare cancers
por: Naing, Aung, et al.
Publicado: (2020) -
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
por: Colen, Rivka R, et al.
Publicado: (2021)